A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 560 participants.

Also called NCT07835984

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 560 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07835984
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07835984. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
Condition
Hypertension
Intervention (Drug)
GW906
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07835984
Content hash
9a116b3672db4acbc2a167022d4335600e08e9c35338831182376a95264a9653